Royalty Pharma PLC's stocks have recently attracted multiple institutional investors, including Korea Investment CORP, Capital International Investors, and Russell Investments Group Ltd. The firm's stock price has hit a 52-week high of $46.14 USD. TD Cowen recently raised the price target on Royalty Pharma's stocks from $45 to $50. The company's expansion into Asia has been recognized as a positive move with Kenneth Sun appointed to lead the initiative. Its $250M deal with Zymeworks for a cancer drug has also drawn attention. Royalty Pharma's 2026 growth outlook is promising with good earnings projected. The company's valuation has been adjusted amid strong market performance metrics. Various entities, including Vanguard Group Inc. and Citigroup Inc., have decreased their shares in Royalty Pharma, whereas others like Neo Ivy Capital Management and Goodman Advisory Group LLC have bought new positions. The company achieved its investment targets sooner than expected and closed a powerful fiscal year with strong 2025 results, sparking discussions about its undervaluation.
Royalty Pharma Stocks News Analytics from Fri, 29 Aug 2025 07:00:00 GMT to Fri, 13 Mar 2026 15:25:29 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 2
